MedTrace Logo

Study of Radiolabeled ALXN2050 in Healthy Adult Males

NCT04609670 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-01-25

No results posted yet for this study

Summary

This is an open-label study to assess the absorption, metabolism, excretion, and mass balance of a single oral dose of carbon-14 (\[14C\])-ALXN2050 in healthy adult males.

Conditions

  • Healthy

Interventions

DRUG

[14C]-ALXN2050

A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2021-08-23
Completion
2021-08-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04609670 on ClinicalTrials.gov